Scientific Publications Database
Article Title: Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine TumorsAuthors: Singh, Simron; Moody, Lesley; Chan, David L.; Metz, David C.; Strosberg, Jonathan; Asmis, Timothy; Bailey, Dale L.; Bergsland, Emily; Brendtro, Kari; Carroll, Richard; Cleary, Sean; Kim, Michelle; Kong, Grace; Law, Calvin; Lawrence, Ben; McEwan, Alexander; McGregor, Caitlin; Michael, Michael; Pasieka, Janice; Pavlakis, Nick; Pommier, Rodney; Soulen, Michael; Wyld, David; Segelov, Eva
Journal: JAMA ONCOLOGY Volume 4 Issue 11
Date of Publication:2018
Abstract:
There is no consensus on optimal follow-up for completely resected gastroenteropancreatic neuroendocrine tumors. Published guidelines for follow-up are complex and emphasize closer surveillance in the first 3 years after resection. Neuroendocrine tumors have a different pattern and timescale of recurrence, and thus require more practical and tailored follow-up. The Commonwealth Neuroendocrine Tumour Collaboration convened an international multidisciplinary expert panel, in collaboration with the North American Neuroendocrine Tumor Society, to create patient-centered follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. This panel used the RAND/UCLA (University of California, Los Angeles) Appropriateness Method to generate recommendations. A large international survey was conducted outlining current the surveillance practice of neuroendocrine tumor practitioners and shortcomings of the current guidelines. A systematic review of available data to date was supplemented by recurrence data from 2 large patient series. The resultant guidelines suggest follow-up for at least 10 years for fully resected small-bowel and pancreatic neuroendocrine tumors and also identify clinical situations in which no follow-up is required. These recommendations stratify follow-up strategies based on evidence-based prognostic factors that allow for a more individualized patient-centered approach to this complex and heterogeneous malignant neoplasm.